Skip to main content
. 2017 Sep 20;7:11929. doi: 10.1038/s41598-017-12180-2

Table 1.

Baseline Characteristics of the Derivation and Validation Cohorts, median (IQR), or N (%), or means±SD.

Variable Derivation Cohort, n = 2631 Validation Cohort, n = 963 P Value
Demographics
  Age, yrs 61.8 ± 11.6 61.3 ± 11.3 0.221
  Female 825 (31.4) 278 (28.9) 0.152
Medical history
History of Diabetes Mellitus 955 (36.3) 296 (30.7) 0.002
  History of Hypertension 1488 (56.6) 550 (57.1) 0.765
  History of Dyslipidemia 1734 (65.9) 680 (70.6) 0.008
  Current/recent smoker 1360 (51.7) 499 (51.8) 0.947
History of renal dysfunction 212 (8.1) 78 (8.1) 0.967
  History of MI 186 (7.1) 91 (9.4) 0.018
  Prior PCI 205 (7.8) 100 (10.4) 0.014
Prior peripheral arterial disease 26 (1.0) 15 (1.6) 0.155
Presentation
  SBP on admission, mm Hg 134.4 ± 22.7 135.7 ± 22.6 0.136
  Heart rate on admission, beats/min 75.2 ± 14.2 75.3 ± 14.0 0.221
  LVEF, % 57.0 ± 9.6 58.6 ± 8.5 <0.001
  SI 0.58 ± 0.15 0.57 ± 0.14 0.298
  GRACE 130.9 ± 35.3 119.3 ± 34.5 <0.001
Diagnosis on admission 0.028
  Unstable Angia 776 (29.5) 302 (31.4)
  NSTEMI 869 (33.0) 273 (28.3)
  STEMI 986 (37.5) 388 (40.3)
Troponin-I on admission, ng/mL 0.71 (0.01, 17.67) 0.67 (0.01, 21.00) 0.900
PCI details
  Left main disease 249 (9.5) 84 (8.7) 0.497
  Three-vessel disease 806 (30.6) 247 (25.6) 0.004
  Intra-aortic Balloon Pump 135 (5.1) 25 (2.6) 0.001
  TIMI flow grade 3 post PCI 2622 (99.7) 958 (99.5) 0.450
Use of glycoprotein IIb/IIIa inhibitor 827 (31.4) 376 (39.0) <0.001
Medical treatment at discharge
  Aspirin 2532 (96.2) 955 (99.2) <0.001
Clopidogrel 2511 (95.4) 938 (97.4) 0.008
  Ticagrelor 32 (1.2) 12 (1.2) 0.943
  Statin 2491 (94.7) 947 (98.3) <0.001
ACEI / ARBs 1509 (57.4) 401 (41.6) <0.001
Beta-blockers 1414 (53.7) 386 (40.1) <0.001

MI, myocardial infarction; bpm, beats per minute; LVEF, left ventricular ejection fraction; h, hour; PCI, percutaneous coronary intervention; ACEI / ARBs, Angiotensin-converting enzyme inhibitors / Angiotensin receptor blockers.